A Phase I Study Evaluating the Safety and Efficacy of TGR 1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 06 Jul 2017
At a glance
- Drugs Umbralisib (Primary) ; Bevacizumab; Fluorouracil; Folinic acid; Gemcitabine; Oxaliplatin; Paclitaxel
- Indications Colorectal cancer; Gastric cancer; Gastrointestinal stromal tumours; Oesophageal cancer; Pancreatic cancer
- Focus Adverse reactions
- Sponsors TG Therapeutics Inc
- 28 Jun 2017 Planned End Date changed from 1 Jul 2017 to 1 Dec 2017.
- 28 Jun 2017 Planned primary completion date changed from 1 May 2017 to 1 Nov 2017.
- 28 Jun 2017 Status changed from recruiting to active, no longer recruiting.